Search

The article discusses some of the missteps and miscalculations by different groups that left the Iraqi security forces weakened and vulnerable to the 2014 attack and invasion by the Islamic State of Iraq and Syria. Topics covered include the decision of the U.S. State Department to cut civilian programs and listening after the pullout of U.S. troops in 2011 and former State Secretary Hillary Clinton's support for a strong U.S. presence in Iraq.

The article examines the record of Democrat U.S. Presidential candidate Hillary Clinton in regulating the banking industry in the country as of November 2015. According to Clinton, she will be tough on the sector if elected president. Also examined are Clinton's mixed record on the industry, including her request for the voluntary suspension of foreclosures and a freeze on interest rates on adjustable subprime mortgages in 2007, as well as the bills she filed in the U.S. Senate.

The article reports that pharmaceutical company Johnson & Johnson has won a lawsuit alleging that its pain reliever Tylenol was defectively designed. The jury decided that plaintiff Regina Jackson, who had claimed that an overdose of the drug led to her hospitalization, failed to prove that she took Extra Strength Tylenol. McNeil Consumer Healthcare spokeswoman Jodie Wertheim noted that Tylenol has a long history of studies supporting its safety and efficacy.

The article reports on the controversy over the pain reliever Tylenol in the U.S. Internal company records have emerged in a trial pitting Tylenol maker McNeil Consumer Healthcare against a New Jersey woman who claims that she got hospitalized because of the drug. Previously undisclosed documents state that McNeil's regular surveys show that doctors recommended the drug, but they told patients to take the medication at lower doses. Doses near the recommended level could result in liver injury.

The article reports on efforts of the makers of Tylenol painkiller to block safety restrictions imposed by the U.S. Food and Drug Administration (FDA) on its chief ingredient acetaminophen. Topics discussed include study showing acetaminophen as a leading cause of liver failure across the U.S., suggestion of Jodie Wertheim, spokeswoman at McNeil, for customers to follow product label, and campaigns by McNeil Consumer Healthcare to block regulations imposed by FDA.

The article reports that Food and Drug administration (FDA) has approved endorsed introduction of flow restrictors which can help prevent children from taking too much acetaminophen, the active ingredient in Tylenol, which can cause liver damage if taken in high doses. The FDA has left the design of this product to the industry. The article also reports that the standards to test the efficacy of the product is expected in 2016 by American Society for Testing and Materials (ASTM).

The article discusses lawsuit by telecom consultant and whistelblower Todd Heath against AT&T and its unit Wisconsin Bell defrauding E-Rate, federal program subsidizing internet and telephone services to avert digial divide for schools and libraries, an appeals court in D.C. reviving both lawsuits under U.S. False Claims Act calling the AT&T case arise from a centralized and nationwide corporate policy. Article quotes AT&T that it complies with lowest corresponding price and E-Rate.

The article discusses Canada's top health agency's move to consider lowering the maximum daily dose of Acetaminophen in Tylenol and other painkillers, in the wake of the Canadian daily newspaper, Toronto Star's investigation results. Topics discussed include liver damage and deaths caused by drug overdose, excess dosage caused by taking several medicines containing acetaminophen, and Food and Drug Administration's slow progress in the monograph process to regulate over-the-counter drugs.

The article discusses the Food and Drug Administration's (FDA) investigation on the risk of brain deposits in patients, who are given repeated Magnetic Resonance Imaging scans (MRIs), and states that doctors should limit MRIs as image-enhancing drugs containing the metal gadolinium are used. It discusses the research on the nine agents used in the scan, the FDA's recommendation to avoid the drugs Omniscan, Magnevist and Optimark, and the studies by manufacturers to report gadolinium retention.

This article discusses the harmful effects of the drugs injected to help in enhancing MRI (Magnetic Resonance Imaging) scan images. It mentions the retaining of gadolinium based contrast agents like Omniscan and Magnevist produced by GE Health care and Bayer Healthcare respectively. It also briefs on the review of these two drugs by the United States Food and Drug Administration FDA as it contains a potential harmful toxic metal gadolinium that is wound up in the brain tissues of MRI patients.

The article inquires about the uncertainty of risk of asthma-related death posed by Advair asthma drug even after 15 years of its approval by the regulators.

The article discusses the hacked emails from the account of journalist Sydney Blumenthal that disclosed the information he sent to former Secretary of State Hillary Clinton regarding the militant attacks on the U.S. diplomatic outpost in Benghazi, Libya in 2012 that left four dead and 10 people injured. The hacked emails indicate that the information was gathered by a secret spy network that included a former clandestine service officer of the U.S. Central Intelligence Agency (CIA).

The article presents a list of the issues of political accountability by former U.S. Secretary of State Hillary Clinton from 1992 to 2015, which include campaigns on the release of commodity trade tax returns, issues of health care system reform and disclosures to the family foundation donors.

An excerpt from the book "Her Way: The Hopes and Ambitions of Hillary Rodham Clinton" by Jeff Gerth and Don Van Natta Jr. is presented which focuses on the improper used of personal email account by politician Hillary Clinton, during her tenure as U.S. secretary of state.

The article focuses on the book "Stress Test" by Timothy Geithner, former treasury secretary of the U.S. where he discusses American banking company Citigroup. Topics include regulating the financial status of Citigroup during Geithner's tenure as president of the Federal Reserve Bank of New York, Geithner's comment on the capital adequacy of Citigroup, and Geithner's mentor Robert Rubin.

The article evaluates safety and use of over-the-counter drugs including Acetaminophen, ingredient in Tylenol as the U.S. Food and Drug Administration (FDA) have launched a review, reports the drug can cause liver damage, death and the FDA has yet to finalize rules governing the safe use of it.

The article focuses on the move of the U.S. Food and Drug Administration to conduct a review about the regulation of non-prescription drugs including acetaminophen, the active ingredient in Tylenol. It reveals that nearly 150 individuals die every year from accidentally taking too much of acetaminophen. Other issues related to the regulation of non-prescription drugs are mentioned.

The article presents the consumption of acetaminophen beyond prescribed dosage for pain relief by consumers, they are able to buy pills over the counter at gas stations and grocery stores, though considered safe when taken as recommended, overdoses causes liver damage and even death.

The article reports on a call by Dr. Daniel Budnitz in 2008 to install a flow restrictor to medicine bottles to lessen drug overdose-related deaths in children. However, an investigation revealed that the said request remained unfulfilled in 2013 due to cost concerns of the pharmaceutical industry and lack of action by the federal government. Also provided is information regarding medicine products with safety feature.

The article discusses a poll which showed that most Americans may have a wrong understanding of the risks of Tylenol. While half are not aware of any safety warnings involving Tylenol, 80% said that overdosing on the medicine may lead to serious side effects and 35% claimed it was safe to mix Tylenol with another medicine containing acetaminophen. The results suggest a mixed record of success for the labels on Tylenol packages designed to warn consumers on the dangers of the drug.

The article provides incidents of acetaminophen poisoning including a mix-up of two Tylenol products that threatened a baby's life. It cites the case of 5-month old baby of Christina Hutto, Brianna who was prescribed with Tylenol and within days was lying comatose due to an accidental overdose of Tylenol. In a lawsuit filed by the Huttos, Opelousas General Hospital and the attending physician claimed responsibility for giving the Huttos the wrong dosing information and settled with the couple.

The article provides information on acetaminophen, an active ingredient in Tylenol and considered safe when taken at recommended doses. Federal data from Center for Disease Control (CDC) showed that about 150 Americans die a year by accidentally taking too much acetaminophen. According to the Food and Drug Administration, acetaminophen has a narrow safety margin meaning the does that helps is close to the dose that can cause serious harm.

The article discusses data showing how many people die from acetaminophen overdosing. Data compiled by the U.S. Food and Drug Administration (FDA) linked as many as 980 deaths in a year to drugs with acetaminophen and reports of death related with acetaminophen have been increasing faster than those for aspirin, ibuprofen and other common over-the-counter pain medicines. It notes however that only a tiny fraction of people taking acetaminophen seen to suffer injuries or fatalities as a result.

The article focuses on the safe use of acetaminophen as one of the most popular pain relievers in the U.S. The active ingredient in Tylenol is said to be acetaminophen that should be taken in recommended doses as taking large amounts could lead to liver disease or death. It cites studies on the risks of acetaminophen as submitted to the U.S. Food and Drug Administration (FDA) but measures have been delayed that there have been 1,500 deaths of Americans reported due to taking higher doses.

The article reports on the victory of the U.S. Internal Revenue Service (IRS) over a big tax court trial against the Bank of New York Mellon Corp. It mentions that the bank improperly claimed foreign tax credits through financial services firm Barclays PLC's deal which capitalized the tax rates and rules of various countries allowing minimum tax payments among American financial companies. It notes that it will accept a charge of $850 million in response to the ruling and would also appeal.

The article informs on the new rule of the U.S. Federal Communications Commission (FCC) that mandates the telecom companies to charge low fees from the schools and libraries using their services, in the U.S. It is mentioned that the E-rate is a school program that was launched in 1997 under which the schools should be provided with telecom services at the lowest corresponding prices but operators like AT&T and Verizon violated the rule. Also, FCC is launching a training program for operators.

The article focuses on a legislative bill issued by the U.S. Congress which forces phone companies to reduce their call rates to schools and to subsidize the cost of equipment and services. It states that AT&T has charged local school districts much higher rates than it gave to similar customers or more than what the program allowed. It mentions that the leading companies have hired employee to oversee the program which provides training or guidance to phone companies.

The article presents information related to the lawsuit between the U.S. Justice Department, and American International Group Inc. (AIG), that was filed in the Southern District of New York. It involved transactions of more than 2 billion dollars in financing with foreign banks, that culminated in 62 million dollars in tax credits. According to participants in the structured-finance market, some documents of the case read like a primer in the cross-border finance market.

The article presents a discussion on the check-the-box rule of the U.S. The rule permits the country's firms to strip profits from operations in high-tax countries, with the help of an Internal Revenue Service (IRS) form. The form transforms subsidiaries into what the IRS calls a 'disregarded entity.' The existence of nearly 8,000 disregarded entities was reported by the Treasury, by March 2000.

The article presents a discussion on issues concerning the complicated tax scheme called STARS, including Barclays PLC and other U.S. banks. It is stated that nearly 800 million dollars in tax savings were realized by Barclays from the government of Great Britain, in the STARS deals. Also, U.S. banks like BB&T, Bank of New York Mellon Corp., and Wells Fargo were struggling with the government over tax credits claimed by them through STARS.

The article presents information on several strategies of General Electric Co. (GE)adopts for taxation below the top U.S. corporate rate of 35%. General Electric's tax department is stated to be famous for inventing ways to pay people less. It is stated that lower the taxes GE reports the higher is its publicly reported profits.

The article presents information on the controversy over General Electric Co.'s taxes.News about GE made headlines in several newspapers which discusses GE's 2010 financial results, it's tax bill and tax benefit of 3.2 billion claimed by the company. It is stated that GE made the situation worse by putting complicated, technical statements on its website.

It has been stated that the case that would have disclosed evidence that General Electric's Omniscan, a drug used to enhance Magnetic Resonance Imaging (MRIs), cause hundreds of kidney patients to suffer nephrogenic system fibrosis, has been settled on late Sunday night with plaintiff Loralei Knase. It has been stated that officials with GE Healthcare, the unit that makes Omniscan, have stated that the settlement does not mean that the firm is involved in wrongdoings.

The article informs that General Electric Co. (GE) will face a trial on the charges that its drug Omniscan has caused a rare crippling diseases, the drug has been used for enhancing the performance of the magnetic resonance imaging (MRIs) in the U.S. The case will commence from January 17, 2011 at the U.S. District Court in Cleveland, Ohio. Also, GE has constantly supported its drug but opponent claimed that it failed to protect consumers from the drug's side effects.

The article reports that according to the documents released by the U.S. Federal Reserve Board, General Electric Co. (GE) was one of the major user of the Fed's rescue program, the Commercial Paper Funding Facility, in 2008. Also, GE borrowed around 16 billion dollars through by selling commercial papers through Fed. However, from the year 2009 GE started using the program of the Federal Deposit Insurance Corporation which provided subsidized guarantees for medium and short-term loans from banks.

The article reports that the U.S. Food and Drug Administration (FDA) has said that GE Healthcare's Omniscan and two other magnetic resonance imaging drugs should not be used in patients with severely impaired kidneys because they risk developing nephrogenic systemic fibrosis (NSF). The decision brings U.S. labeling requirements for Omniscan and the other drugs more in line with those in Europe. GE Healthcare now faces hundreds of lawsuits from patients who contracted NSF.

The article offers information on the violation of the Danish drug reporting law by General Electric Co. (GE). It states that the company's health care unit failed to promptly and completely inform regulators about a patient who died after experiencing adverse effects from the company's MRI drug Omniscan.

The article discusses a court case ruling wherein, the U.S. District Judge Dan Polster in Cleveland, Ohio has given plaintiffs' lawyers wide latitude to present evidence and expert testimony that GE Healthcare company's Omniscan imaging drug caused nephrogenic systemic fibrosis (NSF), in magnetic resonance imaging (MRI) patients with kidney problems. Lawyers for NSF victims claim that GE failed to adequately warn doctors and patients about the dangers.

The article reports that the U.S. Securities & Exchange Commission (SEC) is looking into records of General Electric Co. (GE) related to its financial crisis as the book "On the Brink: Inside the Race to Stop the Collapse of the Global Financial System," by Hank Paulson states that GE faced financial though did not tell about it. The book states that GE's chief executive officer (CEO) Jeff Immelt told him that the company was facing financial problems though told investors that it was strong.

The article reports that General Electric (GE) Healthcare Inc. restricted the use of its imaging drug, Omniscan, after the drug was linked to a potentially crippling disease, according to reports in Europe. It states that after being pressurized by federal drug regulators, GE and manufacturers of similar drugs revised their labels, warning that patients with serious kidney impairment have greater risk of nephrogenic systemic fibrosis.

The article focuses on the issue of lack of cooperation among financial regulatory bodies in the U.S. related to the management of the financial crises. It analysis the possibility related to the elimination and creation of new administrative agencies for risk assessment and consumer protection and stresses on the need of higher levels of information sharing and decision making among these regulating agencies.

The article offers information on the functioning of treasury secretary Timothy Geithner as president of the U.S. Federal Reserve. It states that the Financial Crisis Inquiry Commission disclosed that a peer review study by other Federal Reserve banks in 2005 found that the New York Fed had insufficient resources to conduct supervisory activities of Citigroup Inc.

The article informs about the settlement between GE HealthCare and the Danish Radiologist, Henrik Thomsen, on the libel lawsuit filed by the company against Thomsen for raising question on its healthcare drug, named Omniscan. According to Dr. Lynne Gailey, the company's spokeswoman, the company objected Henrik's statement that suggest Omniscan could lead to Nephrogenic Systemic Fibrosis (NSF) disease. It is also given that the terms of negotiation are not publicly declared.

An excerpt from the book "On the Brink: Inside the Race to Stop the Collapse of the Global Financial System," by Henry Paulson, is presented.